MedTrace Logo

Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan

NCT01552954 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 269

Last updated 2014-12-18

Study results available
· View outcomes & findings →

Summary

Purpose of this study

1. Intensive education for low salt diet will be enhance the anti-proteinuric effect of Olmesartan, a popular anti-hypertensive drug of angiotensin II receptor blocker, in Koreans compared to conventional prescription of medication.
2. Intensive education for low salt diet will decrease the amount of 24 hour-urine sodium excretion compared to control group, effectively.

Conditions

Interventions

BEHAVIORAL

Intensive education of low salt diet

For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.

Sponsors & Collaborators

  • Daiichi Sankyo

    collaborator INDUSTRY

  • Daewoong Pharmaceutical Co. LTD.

    collaborator INDUSTRY

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Ho Jun Chin, PhD · Seoul National University Bundang Hospital

  • Chun-Soo Lim, PhD · SMG-SNU Boramae Medical Center

  • Dong Ki Kim, PhD · Seoul National University Hospital

  • Suhnggwon Kim, PhD · Seoul National University Hospital

  • Bum Soon Choi, PhD · Seoul St. Mary's Hospital

  • Sang-Ho Lee, PhD · Kyunghee University

  • Jung-Hwan Park, PhD · Konkuk University

  • Sung Joon Shin, PhD · DongGuk University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-06-30
Completion
2013-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01552954 on ClinicalTrials.gov